Cytosorb^® haemoadsorption: a potential game changer for patients needing myocardial surgical revascularisation

Abstract

Cytosorb, an extracorporeal blood purification system, utilises the principles of haemoadsorption to remove low molecular weight substances from the blood, including multiple cytokines such as interleukin (IL)-1b, IL-6, IL-8, and tumour necrosis factor-α, and anti-platelet drugs aiming to improve clinical outcomes. Given the prominent role of pro-inflammatory cytokines in various inflammatory states, Cytosorb has seen growing application as a therapeutic immunomodulator including surgery. This review focuses on the effects of the use of Cytosorb in patients undergoing coronary artery bypass grafting (CABG) and the indications of removal of cytokines and anti-platelet agents such as ticagrelor. The evidence supports the feasibility and safety profile of Cytosorb, with no device-related adverse events reported in all studies. Initial studies suggest significant potential for Cytosorb in urgent or emergency CABG surgery to remove anti-platelet medication with promising benefits on clinical outcomes including fewer blood product transfusions, decreased length of intensive care unit stay, and lower re-sternotomy rates. Furthermore, a cost saving analysis indicated that intraoperative removal of ticagrelor with Cytosorb would be cost effective in the setting of emergency cardiac surgery. However, the evidence remains inconclusive when Cytosorb is used in elective CABG surgery for cytokine removal. Definite high quality clinical trials for both indications for Cytosorb in CABG surgery are needed to clarify if there is a clinically significant benefit in clinical outcomes. There is substantial trial activity for the application of Cytosorb in higher risk cardiac surgery to establish the place of Cytosorb in future treatment pathways in cardiac surgery.

Keywords

Cardiac surgery / coronary artery bypass grafting / cytokines / anti-platelets / ticagrelor

References

[1] Angheloiu GO,Ruse C,Dasari RR.Ticagrelor removal from human blood.JACC Basic Transl Sci2017;2:135-45. PMCID:PMC6113557

[2] Friesecke S,Gross S,Nierhaus A.Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study.J Artif Organs2017;20:252-9.

[3] Kogelmann K,Scheller M.Hemoadsorption by CytoSorb in septic patients: a case series.Crit Care2017;21:74. PMCID:PMC5366999

[4] Ankawi G,Yang B,Xie P.What have we learned about the use of Cytosorb adsorption columns?.Blood Purif2019;48:196-202

[5] Day JRS.The systemic inflammatory response syndrome and cardiopulmonary bypass.Int J Surg2005;3:129-40.

[6] Hawkes AL,Bidstrup B.Outcomes of coronary artery bypass graft surgery.Vasc Health Risk Manag2006;2:477-84. PMCID:PMC1994021

[7] Laffey JG,Cheng DCH.The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist.Anesthesiology2002;97:215-52

[8] Mukhopadhyay S,Mukherjee TK.Role of TNFalpha in pulmonary pathophysiology.Respir Res2006;7:125. PMCID:PMC1613248

[9] Bakhtiary F,Kleine P.Leukocyte depletion during cardiac surgery with extracorporeal circulation in high risk patients.Inflamm Res2008;57:577-85.

[10] Boueiz A.Regulation of endothelial barrier function by reactive oxygen and nitrogen species.Microvasc Res2009;77:26-34.

[11] Roffi M,Collet JP.2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).Eur Heart J2016;37:267-315.

[12] Kozek-Langenecker SA,Afshari A.Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016.Eur J Anaesthesiol2017;34:332-95.

[13] Hansson EC,Åberg B.Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study.Eur Heart J2016;37:189-97. PMCID:PMC4703906

[14] Vane JR.The mechanism of action of aspirin.Thromb Res2003;110:255-8.

[15] Dobesh PP.Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.Pharmacotherapy2014;34:1077-90. PMCID:PMC4282310

[16] Capodanno D.Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside.J Cardiovasc Transl Res2014;7:82-90.

[17] Garau I,Sehner S.Hemadsorption during cardiopulmonary bypass reduces interleukin 8 and tumor necrosis factor α serum levels in cardiac surgery: a randomized controlled trial.Minerva Anestesiol2019;85:715-23.

[18] Gleason TG,Bavaria JE.Hemoadsorption to reduce plasma-free hemoglobin during cardiac surgery: Results of REFRESH I pilot study.Sem Thorac Cardiovasc Surg2019;31:783-93.

[19] Hohn A,Pietroschinsky E.Hemoadsorption: effective in reducing circulating fragments of the endothelial glycocalyx during cardiopulmonary bypass in patients undergoing on-pump cardiac surgery?.Minerva Anestesiol2021;87:35-42.

[20] Bernardi MH,Dragosits K.Effect of hemoadsorption during cardiopulmonary bypass surgery - a blinded, randomized, controlled pilot study using a novel adsorbent.Crit Care2016;20:96. PMCID:PMC4826492

[21] Bernardi MH,Ristl R,Wiedemann D.Hemoadsorption does not have influence on hemolysis during cardiopulmonary bypass.ASAIO J2019;65:738-43

[22] Poli EC,Bauer-Doerries A.Cytokine clearance with CytoSorb® during cardiac surgery: a pilot randomized controlled trial.Crit Care2019;23:108. PMCID:PMC6448322

[23] Wisgrill L,Hell L.Influence of hemoadsorption during cardiopulmonary bypass on blood vesicle count and function.J Transl Med2020;18:202. PMCID:PMC7229608

[24] Taleska Stupica G,Bozhinovska M.Extracorporeal hemadsorption versus glucocorticoids during cardiopulmonary bypass: A prospective, randomized, controlled trial.Cardiovasc Ther2020;2020:7834173. PMCID:PMC7149340

[25] Hassan K,Wohlmuth P,Schmoeckel M.Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding.Ann Thorac Surg2019;108:45-51.

[26] EuroELSO 2020 Poster Abstracts. Perfusion 2020;35:93-282. https://journals.sagepub.com/doi/pdf/10.1177/0267659120909723

[27] Hassan K,Brüning T.Budget impact analysis of sorbent hemadsorption during emergency cardiac surgery in ticagrelor-loaded patients.Thorac Cardiovasc Surg2020;68:S1-S72

[28] Hassan K,Radtke A.Low bleeding after emergency CABG using CytoSorb adsorption of ticagrelor: A 2-year clinical experience.Thorac Cardiovasc Surg2020;68:S1-S72

[29] Javanbakht M,Rezaei Hemami M.Ticagrelor removal by CytoSorb(®) in patients requiring emergent or urgent cardiac surgery: A UK-based cost-utility analysis.Pharmacoecon Open2020;4:307-19. PMCID:PMC7248150

[30] Mair H,Haas B.Ticagrelor and rivaroxaban elimination with CytoSorb adsorber before urgent off-pump coronary bypass.Ann Thorac Surg2020;110:e369-e70.

[31] Nemeth E,Racz K.Impact of intraoperative cytokine adsorption on outcome of patients undergoing orthotopic heart transplantation-an observational study.Clin Transplant2018;32:e13211